Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group

Bleecker, Eugene R.; Al‐Ahmad, Mona; Bjermer, Leif; Caminati, Marco; Canonica, Giorgio Walter; Kaplan, Alan; Papadopoulos, Nikolaos G.; Roche, Nicolás; Tohda, Yuji; Yáñez, Anahí; Price, David

doi:10.1016/j.waojou.2022.100726

Cited by 19 publications

(11 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When controlling asthma symptoms, physicians should adjust ICS doses to levels that will control the patient's symptoms, rather than prescribing systemic corticosteroids, given the potential risks and harms associated with their use. 35 , 36 Although the importance of ICSs in patients with asthma has always been known, 37 , 38 , 39 our study showed a low ICS prescription rate and frequent SABA prescriptions in these patients. To improve the low ICS prescription rate, physicians should focus on controlling asthma using an ICS-based inhaler.…”

Section: Discussionmentioning

confidence: 61%

Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006–2015

Kim¹,

Lee²,

Park³

et al. 2023

World Allergy Organization Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 61%

Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006–2015

Kim¹,

Lee²,

Park³

et al. 2023

World Allergy Organization Journal

View full text Add to dashboard Cite

“…One possible explanation for this finding could be that patients treated with omalizumab were more severe, and the CV damage may have been a consequence of the drugs used to treat asthma, particularly oral corticosteroids, which have been associated with an increased risk for adverse CVEs. 55 Furthermore, a French pharmacovigilance study found that omalizumab was considerably more related with hypertension, ventricular arrhythmia, and venous thromboembolism than mepolizumab, reslizumab, and benralizumab, which are anti-IL-5 mAbs. 56 However, a pooled review of 25 omalizumab-related RCTs and two extension studies found no indication of increased CV risk.…”

Section: Monoclonal Antibodies the Evaluating Clinicalmentioning

confidence: 99%

Section: Cardiovascular Diseasementioning

confidence: 99%

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cazzola

Rogliani

Ora

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Chronic airway diseases (CAD), mainly asthma and chronic obstructive pulmonary disease (COPD), are frequently associated with different comorbidities. Among them, cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) pose problems for the simultaneous treatment of CAD and comorbidity. Indeed, there is evidence that some drugs used to treat CAD negatively affect comorbidity, and, conversely, some drugs used to treat comorbidity may aggravate CAD. However, there is also growing evidence of some beneficial effects of CAD drugs on comorbidities and, conversely, of the ability of some of those used to treat comorbidity to reduce the severity of lung disease. In this narrative review, we first describe the potential cardiovascular risks and benefits for patients using drugs to treat CAD and the potential lung risks and benefits for patients using drugs to treat CVD. Then, we illustrate the possible negative and positive effects on T2DM of drugs used to treat CAD and the potential negative and positive impact on CAD of drugs used to treat T2DM. The frequency with which CAD and CVD or T2DM are associated requires not only considering the effect that drugs used for one disease condition may have on the other but also providing an opportunity to develop therapies that simultaneously favorably impact both diseases.

show abstract

“…While exacerbations are harmful, the impact of short courses of OCS for exacerbations is underestimated; 38 they are associated with adverse events such as psychiatric effects, osteoporosis, fracture, diabetes, glaucoma, cataracts, atypical infections and even mortality. 39 This risk is magnified in patients on long-term OCS, which have been used to achieve control in patients with more severe asthma. It is important to keep track of those short courses of OCS for exacerbations, as even two courses per year can lead to significant patient risk.…”

Section: Oral Corticosteroid (Ocs) Dangersmentioning

confidence: 99%

Update in the Management and Treatment of Adult Asthma for Primary Care Physicians

Kaplan

2023

Can Prim Care Today

Self Cite

View full text Add to dashboard Cite

Asthma is a common illness; estimates are that it affects up to 18% of the global population, with rates increasing every year. Approximately 3.8 million Canadians have asthma, and these patients continue to suffer from inadequately controlled disease as well as exacerbations. Although we have more medication choice than ever, mortality rates in Canada have not declined. Our current pharmacologic strategy has been mostly unchanged for years; it starts with an anti-inflammatory medication, usually an inhaled corticosteroid (ICS) to treat the type 2 (T2) inflammation that is most common. When an ICS provides inadequate control, therapy is often stepped up to include an ICS/long-acting beta-agonist (LABA) combination and even additional therapies like leukotriene receptor antagonists or long-acting muscarinic agents (LAMAs). As patients with uncontrolled asthma are at risk for deleterious outcomes, controlling the disease and preventing exacerbations should be the goal for all patients.

show abstract

Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group

Cited by 19 publications

References 92 publications

Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006–2015

Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006–2015

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Update in the Management and Treatment of Adult Asthma for Primary Care Physicians

Contact Info

Product

Resources

About